OncoMatch

OncoMatch/Clinical Trials/NCT07107126

Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

Is NCT07107126 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies RPT1G for acute myeloid leukemia.

Phase 1RecruitingRemedy Plan, Inc.NCT07107126Data as of May 2026

Treatment: RPT1GThe main goals of this study are to learn if RPT1G is safe and tolerable and to determine the best dose and schedule of RPT1G for patients with relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Myelodysplastic Syndrome

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Must have received: standard of care therapy

have received appropriate standard of care therapy, in the opinion of the investigator or declined receipt of these

Cannot have received: radiotherapy

Radiotherapy <14 days prior to the first day of RPT1G administration

Lab requirements

Kidney function

creatinine clearance >50 mL/min (Cockcroft-Gault equation, CLIA certified local laboratory)

Liver function

AST ≤2.5 x ULN, ALT ≤2.5 x ULN, and total bilirubin <2 x ULN (exceptions for Gilbert's syndrome and disease-related elevation possible)

Hepatic: AST ≤2.5 x ULN, ALT ≤2.5 x ULN, and total bilirubin <2 x ULN (except for study patients with known Gilbert's where 1.5 x UL of the subject's baseline or in the case of suspected Gilbert's syndrome where a maximum total bilirubin level of 4.0 mg/dL is acceptable) for the local laboratory. If due to disease, higher values may be approved after discussion with medical monitor. Renal: Adequate renal function as defined by calculated creatinine clearance >50 mL/min for the CLIA certified local laboratory. Creatinine clearance must be calculated by Cockcroft-Gault equation.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Memorial Sloan Kettering Cancer Center · New York, New York
  • MD Anderson Cancer Center · Houston, Texas

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify